Oncolytic virus
CA 2386920 C · Owner: University Of Ottawa · Inventors: Atkins, Harold Lawrence; Stojdl, David Francis; Brown, Earl Garnet
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels or no. PKR activity, or as being , PKR-/- STAT1-/- or both PKR-/- and STAT1-/-. The virus is selected from the group consisting of Rhabdovirus and picornavirus and preferably is vesicular , stomatitis virus (VSV) or a derivative thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 18, 2000 and granted January 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 18, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 18, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.